Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

New digital health app plays the way toward a fully autonomous artificial pancreas system – dramatically improving the quality of life for people with Type 1 Diabetes. Klue, a digital health company focused on behavior tracking and positive change, announces its platform’s expansion to Type 1 Diabetes (T1D). Klue is already known for its gesture sensing and analytics technology that promotes mindful eating and proper hydration. Now, it is ready to branch out in diabetes.

Read more ...

Rheonix, announces the launch of its NGS OnePrep™ solution, an integrated, automated method for DNA extraction and next-generation sequencing (NGS) library preparation on the Encompass Optimum™ workstation, at the Association of Molecular Pathology (AMP) Annual Meeting and Expo Nov.1-3 in San Antonio, Texas. The method will allow laboratory technicians to produce sequence-ready libraries directly from raw samples with significantly reduced hands-on time compared with current methods.

Read more ...

Recent advances in genome engineering are starting a revolution in biological and translational applications. CRISPR-Cas9 and its variants enable diverse manipulations of genome function. This genome editing principle spans almost every industry that involves biological systems including: biotech, agritech, therapeutics and diagnostics.

Read more ...

ERS Genomics and DefiniGEN announced a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical human models.

Read more ...

DNA Electronics said that the Biomedical Advanced Research and Development Authority has approved the second phase of a contract for the development of a next-generation sequencing platform for rapid diagnosis of antimicrobial resistant infections and influenza. BARDA, a division of the US Department of Health and Human Services, awarded London-based DNAe $10.98 million so that the firm could develop an "alpha prototype" of the platform. The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.

Read more ...

Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.

Read more ...

Upcoming Events

No events

Presentation

Micromachined Ultrasound Technologies: An Overview of Emerging Trends and Applications
Discover the presentation held by Jérôme Mouly, Senior Technology & Market Analyst, Inkjet...
CRISPR Technology & Market Overview: challenges, market competition landscape and strategic opportunities
Discover the presentation held by Asma Siari, Technology & Market Analyst in Biotechnologies...
Birth of a Future Giant: Zoom on the Chinese Microfluidics Industry
Discover the presentation held by Sébastien Clerc, Market & Technology Analyst, Microfluidi...

Access to all our presentations